MedTrace Logo

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

NCT03836157 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-06-27

No results posted yet for this study

Summary

IMGN853 is designed to inhibit cell division and cell growth of folate receptor 1 (FRα)-expressing tumor cells. The purpose of this study is to test the safety of IMGN853 and bevacizumab and see what effects (good and bad) that this combination treatment has on subjects with recurrent endometrial cancer.

Conditions

  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • Endometrial Serous Adenocarcinoma
  • Endometrial Clear Cell Adenocarcinoma

Interventions

DRUG

Mirvetuximab Soravtansine

The dose will not be recalculated unless the patient has ±10% weight change.

DRUG

Bevacizumab

Subject will receive IMGN853 first followed by bevacizumab. There is no planned delay between the IMGN853 and bevacizumab administration.

Sponsors & Collaborators

  • ImmunoGen, Inc.

    collaborator INDUSTRY

  • University of Oklahoma

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-31
Primary Completion
2021-11-30
Completion
2022-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03836157 on ClinicalTrials.gov